Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Xoma reports Q2 EPS (33c), consensus (38c) » 17:49
08/06/20
08/06
17:49
08/06/20
17:49
XOMA

Xoma

$16.15 /

-0.69 (-4.10%)

Reports Q2 revenue $444K,…

Reports Q2 revenue $444K, consensus $2.27M. "With a healthy cash position, a low-cost infrastructure, and a strict discipline on capital deployment, XOMA remains in a strong position to continue executing on our royalty-aggregator strategy to create near- and long-term value for shareholders. We were pleased to expand our Board of Directors with the appointment of Natasha Hernday, Senior Vice President, Corporate Development at Seattle Genetics, who brings significant expertise in sourcing and executing licensing deals, acquisitions, and partnerships that are complementary to our business model," stated Jim Neal, Chief Executive Officer. "We recognize COVID-19 continues to impact clinical activities broadly across the industry, and while these challenges may affect the timing of potential milestone payments due to XOMA, they also could create opportunities for us to acquire interesting milestone and royalty assets. "We commend our partners for their continued focus on advancing their therapeutic candidates in the face of COVID-19-related challenges. For example, Ology Bioservices was awarded a contract from the Department of Defense to further its anti-botulinum toxin program," Mr. Neal added. "Recently, Sesen Bio announced it signed an exclusive license agreement with Qilu Pharmaceutical for the development and commercialization of Vicineum(TM), a locally administered fusion protein being developed for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC), in Greater China."

ShowHide Related Items >><<
XOMA Xoma
$16.15 /

-0.69 (-4.10%)

XOMA Xoma
$16.15 /

-0.69 (-4.10%)

03/10/20 H.C. Wainwright
Novartis' recent R&D day driving interest in Xoma, says H.C. Wainwright
XOMA Xoma
$16.15 /

-0.69 (-4.10%)

Earnings
Merus reports Q2 EPS (54c), consensus (61c) » 17:27
08/06/20
08/06
17:27
08/06/20
17:27
MRUS

Merus

$13.21 /

-0.22 (-1.64%)

Reports Q2 revenue…

Reports Q2 revenue $6.06M, consensus $7.51M. "We are pleased to report several updates and progress with our business this quarter," said Bill Lundberg, president, CEO and Principal Financial Officer of Merus. "On the clinical side, Dr. Andrew Joe has been appointed Chief Medical Officer, bringing over 20 years of clinical experience developing cancer therapies, including molecularly-targeted and tumor-agnostic therapies, to the Merus team. On the business side, we have prudently focused our projected spend and anticipate our cash runway will fund our operations into the second half of 2022, putting us in a strong financial position. We look forward to providing a substantive clinical update on zenocutuzumab (Zeno) for neuregulin 1 (NRG1) fusion cancers by year end."

ShowHide Related Items >><<
MRUS Merus
$13.21 /

-0.22 (-1.64%)

MRUS Merus
$13.21 /

-0.22 (-1.64%)

06/26/20 H.C. Wainwright
Merus initiated with a Buy at H.C. Wainwright
05/27/20
Fly Intel: Top five analyst downgrades
05/27/20 RBC Capital
Merus downgraded to Sector Perform from Outperform at RBC Capital
05/27/20 RBC Capital
Merus downgraded to Sector Perform from Outperform at RBC Capital
  • 05
    Nov
Syndicate
Iveric bio files to sell 8.65M shares of common stock for holders  17:27
08/06/20
08/06
17:27
08/06/20
17:27
ISEE

Iveric bio

$4.30 /

-0.095 (-2.16%)

 
ShowHide Related Items >><<
ISEE Iveric bio
$4.30 /

-0.095 (-2.16%)

ISEE Iveric bio
$4.30 /

-0.095 (-2.16%)

01/24/20 Cowen
Iveric bio initiated with an Outperform at Cowen
01/07/20
Fly Intel: Top five analyst initiations
01/06/20 Wedbush
Wedbush starts Iveric bio with Outperform rating, $13 price target
01/06/20 Wedbush
IVERIC bio initiated with an Outperform at Wedbush
  • 18
    Jun
  • 06
    Dec
ISEE Iveric bio
$4.30 /

-0.095 (-2.16%)

Earnings
Five Prime reports Q2 EPS (48c), consensus (61c) » 16:36
08/06/20
08/06
16:36
08/06/20
16:36
FPRX

Five Prime

$6.10 /

+0.07 (+1.16%)

"We remain on track…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FPRX Five Prime
$6.10 /

+0.07 (+1.16%)

FPRX Five Prime
$6.10 /

+0.07 (+1.16%)

06/22/20 Wedbush
Five Prime upgraded to Outperform from Neutral at Wedbush
06/22/20 Wedbush
Five Prime upgraded to Outperform from Neutral at Wedbush
02/28/20 JPMorgan
Five Prime downgraded to Underweight from Neutral at JPMorgan
02/28/20 JPMorgan
Five Prime downgraded to Underweight from Neutral at JPMorgan
FPRX Five Prime
$6.10 /

+0.07 (+1.16%)

Syndicate
Kura Oncology files $300M mixed securities shelf  16:35
08/06/20
08/06
16:35
08/06/20
16:35
KURA

Kura Oncology

$17.99 /

+0.34 (+1.93%)

 
ShowHide Related Items >><<
KURA Kura Oncology
$17.99 /

+0.34 (+1.93%)

KURA Kura Oncology
$17.99 /

+0.34 (+1.93%)

07/07/20 Credit Suisse
Kura Oncology initiated with an Outperform at Credit Suisse
05/29/20 Piper Sandler
Kura's tipifarnib updates support tumor agnostic potential, says Piper Sandler
05/29/20 H.C. Wainwright
Kura data 'solidifying' confidence in AIM-HN study, says H.C. Wainwright
05/19/20 Deutsche Bank
Kura Oncology price target lowered to $24 from $28 at Deutsche Bank
KURA Kura Oncology
$17.99 /

+0.34 (+1.93%)

  • 06
    May
Earnings
Kura Oncology reports Q EPS (40c), consensus (42c) » 16:26
08/06/20
08/06
16:26
08/06/20
16:26
KURA

Kura Oncology

$17.99 /

+0.34 (+1.93%)

Cash, cash equivalents…

Cash, cash equivalents and short-term investments totaled $338.9M as of June 30, including net proceeds of approximately $134.9M from a public offering completed in May, compared with $236.9M as of December 31, 2019. "Last quarter we implemented a number of strategic measures to focus on our two major development pillars: tipifarnib in HRAS-dependent head and neck squamous cell carcinoma (HNSCC) and KO-539 in acute myeloid leukemia (AML)," said Troy Wilson, CEO of Kura Oncology. "We believe tipifarnib and KO-539 provide opportunities to address large proportions of head and neck cancers and acute leukemias, respectively. Now, following a successful public offering this past quarter, we are well-positioned to advance each of these programs toward important upcoming catalysts."

ShowHide Related Items >><<
KURA Kura Oncology
$17.99 /

+0.34 (+1.93%)

KURA Kura Oncology
$17.99 /

+0.34 (+1.93%)

07/07/20 Credit Suisse
Kura Oncology initiated with an Outperform at Credit Suisse
05/29/20 Piper Sandler
Kura's tipifarnib updates support tumor agnostic potential, says Piper Sandler
05/29/20 H.C. Wainwright
Kura data 'solidifying' confidence in AIM-HN study, says H.C. Wainwright
05/19/20 Deutsche Bank
Kura Oncology price target lowered to $24 from $28 at Deutsche Bank
KURA Kura Oncology
$17.99 /

+0.34 (+1.93%)

  • 06
    May
Earnings
Y-mAbs Therapeutics reports Q2 EPS ($1.01), consensus (68c) » 16:05
08/06/20
08/06
16:05
08/06/20
16:05
YMAB

Y-mAbs Therapeutics

$39.73 /

+1.19 (+3.09%)

The Company had…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
YMAB Y-mAbs Therapeutics
$39.73 /

+1.19 (+3.09%)

YMAB Y-mAbs Therapeutics
$39.73 /

+1.19 (+3.09%)

05/11/20 Wedbush
Y-mAbs Therapeutics price target raised to $48 from $41 at Wedbush
05/11/20 H.C. Wainwright
Y-mAbs Therapeutics price target raised to $52 from $41 at H.C. Wainwright
05/05/20 Barclays
Y-mAbs Therapeutics initiated with an Overweight at Barclays
05/01/20
Fly Intel: Top five analyst initiations
YMAB Y-mAbs Therapeutics
$39.73 /

+1.19 (+3.09%)

  • 30
    Oct
YMAB Y-mAbs Therapeutics
$39.73 /

+1.19 (+3.09%)

Hot Stocks
Y-mAbs Therapeutics completes Omburtamab BLA submission » 09:01
08/06/20
08/06
09:01
08/06/20
09:01
YMAB

Y-mAbs Therapeutics

$38.54 /

+0.84 (+2.23%)

Y-mAbs Therapeutics…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
YMAB Y-mAbs Therapeutics
$38.54 /

+0.84 (+2.23%)

YMAB Y-mAbs Therapeutics
$38.54 /

+0.84 (+2.23%)

05/11/20 Wedbush
Y-mAbs Therapeutics price target raised to $48 from $41 at Wedbush
05/11/20 H.C. Wainwright
Y-mAbs Therapeutics price target raised to $52 from $41 at H.C. Wainwright
05/05/20 Barclays
Y-mAbs Therapeutics initiated with an Overweight at Barclays
05/01/20
Fly Intel: Top five analyst initiations
YMAB Y-mAbs Therapeutics
$38.54 /

+0.84 (+2.23%)

  • 30
    Oct
YMAB Y-mAbs Therapeutics
$38.54 /

+0.84 (+2.23%)

Hot Stocks
Sierra Oncology names Kevin Norrett as Chief Business Officer » 08:22
08/06/20
08/06
08:22
08/06/20
08:22
SRRA

Sierra Oncology

$11.72 /

-0.305 (-2.54%)

Sierra Oncology announced…

Sierra Oncology announced the appointments of Kevin Norrett as Chief Business Officer and William Turner as Chief Regulatory and Technical Operations Officer. Most recently, Kevin was Chief Commercial Officer at Angion Biomedica, a clinical stage company with a focus in acute organ injury and fibrosis. Turner was Senior Vice President of Technical Operations and Regulatory Science at Aimmune Therapeutics for several years.

ShowHide Related Items >><<
SRRA Sierra Oncology
$11.72 /

-0.305 (-2.54%)

SRRA Sierra Oncology
$11.72 /

-0.305 (-2.54%)

07/30/20
Fly Intel: Top five analyst initiations
07/30/20 H.C. Wainwright
Sierra Oncology initiated with a Buy at H.C. Wainwright
12/06/19
Fly Intel: Top five analyst initiations
12/05/19 Oppenheimer
Sierra Oncology initiated with an Outperform at Oppenheimer
SRRA Sierra Oncology
$11.72 /

-0.305 (-2.54%)

SRRA Sierra Oncology
$11.72 /

-0.305 (-2.54%)

Earnings
Sierra Oncology reports Q2 EPS ($1.58), consensus ($1.63) » 08:05
08/06/20
08/06
08:05
08/06/20
08:05
SRRA

Sierra Oncology

$11.72 /

-0.305 (-2.54%)

"We believe…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SRRA Sierra Oncology
$11.72 /

-0.305 (-2.54%)

SRRA Sierra Oncology
$11.72 /

-0.305 (-2.54%)

07/30/20
Fly Intel: Top five analyst initiations
07/30/20 H.C. Wainwright
Sierra Oncology initiated with a Buy at H.C. Wainwright
12/06/19
Fly Intel: Top five analyst initiations
12/05/19 Oppenheimer
Sierra Oncology initiated with an Outperform at Oppenheimer
SRRA Sierra Oncology
$11.72 /

-0.305 (-2.54%)

SRRA Sierra Oncology
$11.72 /

-0.305 (-2.54%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.